If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...
NEW DELHI: Rudrabhishek Enterprises (REPL) has received registration for small and medium real estate investment trusts (SM REITs) by the securities and exchange board of India (SEBI). SEBI first ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback